Clinical use of mood stabilizers beyond treatment for bipolar disorder: The REAP-MS study.

[1]  Takahiro A. Kato,et al.  Coprescription of mood stabilizers in schizophrenia, dosing, and clinical correlates: An international study , 2020, Human psychopharmacology.

[2]  M. Frye,et al.  Dissecting the Epigenetic Changes Induced by Non-Antipsychotic Mood Stabilizers on Schizophrenia and Affective Disorders: A Systematic Review , 2020, Frontiers in Pharmacology.

[3]  L. Baandrup.  Polypharmacy in schizophrenia. , 2020, Basic & clinical pharmacology & toxicology.

[4]  S. Kasper,et al.  Psychopharmacological Treatment of Schizophrenia Over Time in 30 908 Inpatients: Data From the AMSP Study , 2019, The international journal of neuropsychopharmacology.

[5]  M. Olfson,et al.  Comparative Effectiveness of Adjunctive Psychotropic Medications in Patients With Schizophrenia , 2019, JAMA psychiatry.

[6]  K. Sim,et al.  Polypharmacy and psychotropic drug loading in patients with schizophrenia in Asian countries: Fourth survey of Research on Asian Prescription Patterns on antipsychotics , 2018, Psychiatry and clinical neurosciences.

[7]  J. Calabrese,et al.  Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder , 2018, Bipolar disorders.

[8]  H. Möller,et al.  The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Acute and long-term treatment of mixed states in bipolar disorder , 2018, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[9]  T. Outhred,et al.  The use of lithium for the treatment of bipolar disorder: Recommendations from clinical practice guidelines. , 2017, Journal of affective disorders.

[10]  S. Kanba,et al.  Clinical Use of Mood Stabilizers With Antidepressants in Asia: Report From the Research on Asian Psychotropic Prescription Patterns for Antidepressants (REAP-AD) Projects in 2004 and 2013 , 2017, Journal of clinical psychopharmacology.

[11]  A. Young,et al.  The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 3: The Clinical Guidelines , 2016, The international journal of neuropsychopharmacology.

[12]  S. Leucht,et al.  Valproate for schizophrenia. , 2016, The Cochrane database of systematic reviews.

[13]  L. Proietti,et al.  Pharmacologic approaches to treatment resistant depression: Evidences and personal experience. , 2015, World journal of psychiatry.

[14]  R. Canitano.  Mood Stabilizers in Children and Adolescents With Autism Spectrum Disorders , 2015, Clinical neuropharmacology.

[15]  K. Min,et al.  Korean Medication Algorithm for Depressive Disorder: Comparisons with Other Treatment Guidelines , 2014, European Neuropsychopharmacology.

[16]  T. Bschor.  Lithium in the Treatment of Major Depressive Disorder , 2014, Drugs.

[17]  H. Belli,et al.  Borderline Personality Disorder: Bipolarity, Mood Stabilizers and Atypical Antipsychotics in Treatment , 2012, Journal of clinical medicine research.

[18]  C. Rosen,et al.  Concordance between psychotropic prescribing for veterans with PTSD and clinical practice guidelines. , 2012, Psychiatric services.

[19]  F. Dickerson,et al.  Adjunctive Mood Stabilizer and Benzodiazepine Use in Older Asian Patients with Schizophrenia, 2001–2009 , 2012, Pharmacopsychiatry.

[20]  L. Citrome,et al.  Schizoaffective Disorder , 2011, CNS drugs.

[21]  I. Glick,et al.  A Double-Blind Randomized Trial of Mood Stabilizer Augmentation Using Lamotrigine and Valproate for Patients With Schizophrenia Who Are Stabilized and Partially Responsive , 2009, Journal of clinical psychopharmacology.

[22]  H. Möller,et al.  What is the optimal serum lithium level in the long-term treatment of bipolar disorder--a review? , 2008, Bipolar disorders.

[23]  A. Berghöfer,et al.  Prophylaxis of schizoaffective disorder with lithium or carbamazepine: outcome after long-term follow-up. , 2004, Journal of affective disorders.

[24]  S. Ghaemi.  On defining 'mood stabilizer'. , 2001, Bipolar disorders.

[25]  J. Cade.  Lithium salts in the treatment of psychotic excitement. , 1949, The Medical journal of Australia.

[26]  J. Passchier,et al.  Effectiveness of pharmacotherapy for severe personality disorders: meta-analyses of randomized controlled trials. , 2010, The Journal of clinical psychiatry.

[27]  J. Levine,et al.  Utilization of Valproate: Extent of Inpatient Use in the New York State Office of Mental Health , 2004, Psychiatric Quarterly.

[28]  S. Strakowski,et al.  New developments in the pharmacologic treatment of schizoaffective disorder. , 1996, The Journal of clinical psychiatry.